Novavax to Present at the 33rd Annual J.P. Morgan Healthcare Conference
January 07 2015 - 10:17AM
GAITHERSBURG, Md., Jan. 7, 2015 (GLOBE NEWSWIRE)
-- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage biopharmaceutical
company focused on the discovery, development and commercialization
of recombinant nanoparticle vaccines and adjuvants, today announced
that Stanley C. Erck, President and CEO, will present at the
33rd Annual J.P.
Morgan Healthcare Conference on Wednesday, January 14, 2015 at
11:30 a.m. PT in San Francisco, CA at The Westin St. Francis
Hotel.
A live webcast link for the presentation will be
available via the company's website at www.novavax.com under
Investor Info/Events.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage
biopharmaceutical company creating vaccines and vaccine adjuvants
to address a broad range of infectious diseases worldwide. Using
innovative proprietary recombinant nanoparticle vaccine technology,
the company produces vaccine candidates to efficiently and
effectively respond to both known and newly emergent diseases.
CONTACT: Barclay A. Phillips
SVP, Chief
Financial Officer and Treasurer
Novavax,
Inc.
240-268-2000
This
announcement is distributed by NASDAQ OMX Corporate Solutions on
behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Novavax, Inc. via Globenewswire
HUG#1885102
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Apr 2023 to Apr 2024
